Effect of C-peptide on Hypoglycemic Counterregulation

Iatrogenic hypoglycemia is the most prominent barrier to the safe, effective management of blood sugar in people with type 1 diabetes due to periodic over-insulinization. During insulin-induced hypoglycemia, glucagon secretion is diminished in type 1 diabetes which, in turn, reduces hepatic glucose production and increases the depth and duration of hypoglycemic episodes. We have observed that the naturally occurring protein C-peptide increases glucagon secretion in dogs during insulin-induced hypoglycemia, which increases hepatic glucose production; the experiments in this application will shed light on the translation of this finding to the human.

NCT Number	NCT06470295
Lead Sponsor	University of Cincinnati
Conditions	Hypoglycemia, Type 1 Diabetes
Enrollment	38 participants
Start Date	2024-06-01
Primary Completion	2027-06-01 (estimated)
Study Completion	2028-01-01 (estimated)
Updated on ClinicalTrials.gov	2026-02-17